ALK and non-small cell lung carcinoma: Based on prospective cohort studies, recently the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for metastatic NSCLC recommended the use of next-generation TKI for patients with a druggable oncogene driver (EGFR, ALK) and clinically asymptomatic BM [46].